CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
to Standard Of Care in adult patients with aggressive B-cell Non-Hodgkin Lymphoma after failure of rituximab and anthracyc...
Phase 3
Taipei, Taiwan and 66 other locations
tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of DR-0201 in adult patients with relapsed or refractory B-cell non...
Phase 1
Taipei, Taiwan and 15 other locations
The purpose of this study was to evaluate whether copanlisib in combination with rituximab is superior to placebo in combination with rituximab in pr...
Phase 3
Taipei, Taiwan and 186 other locations
tolerability of CHO-H01 in subjects with relapsed/refractory CD20+ non-Hodgkin's lymphoma. It will also determine maximum ...
Phase 1, Phase 2
Taipei, Taiwan and 7 other locations
is focused on patients with previously treated aggressive B-cell non-Hodgkin lymphoma whose cancer has stopped responding ...
Phase 3
Taipei, Taiwan and 53 other locations
B-cell Lymphoma is an aggressive and rare cancer of a type of immune cell (a white blood cell responsible for fighting infections). The purp-...
Phase 2
Taipei, Keelung, Taiwan and 74 other locations
The purpose of the study is to determine the recommended Phase 2 dose(s) (RP2D\[s\]) in B cell non-Hodgkin lymphoma (NHL) ...
Phase 1
Taipei, Taiwan and 14 other locations
The main purpose of this study is to characterize safety and to determine the recommended phase 2 dose (RP2D) for JNJ-88998377 (Part A: Dose Escalati...
Phase 1
Taipei, Taiwan and 14 other locations
bispecific antibody, in subjects with relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL) who have received 2 or mo...
Phase 1
Taipei, Taiwan and 28 other locations
monotherapy in adult participants with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL) who have received at least tw...
Phase 2
Taipei City, Taiwan and 44 other locations
Clinical trials
Research sites
Resources
Legal